Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 03/11/17 at 10:28am

As we move into November, we bring you another run down of the top ten most popular articles on Pharmafile.com this week.

Novartis' has revealed the data behind the approval of its CAR-T therapy Kymriah as it became the first-ever such treatment approved by the FDA. Gilead entered the fray weeks later with its own approval, and the CAR-T space is now heating up. We delved into this area for an in-depth feature exploring the huge promise it presents.

But the most popular story this week was the news that Samsung Biologics and MSD have reinforced their biologics manufacturing and development partnership.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Over-the-counter multinutrient drink could have beneficial impact on Alzheimer's, new study reveals

New data on Fortasyn Connect – also known as Souvenaid – an over-the-counter multinutrient drink which claims to be able to delay the development of Alzheimer’s disease, has revealed it could actually present beenfits for patients.

9. GSK's 'bubble boy' gene therapy secures NICE recommendation despite high cost

GSK's Strimvelis, its gene therapy treatment for adenosine deaminase deficiency or ‘bubble boy’ syndrome, has been given a positive recommendation by NICE despite the extremely high cost associated with it. 

8. AstraZeneca asthma therapy tralokinumab flops at Phase 3

AstraZeneca and MedImmune, the company’s global biologics research and development arm, have announced new Phase 3 data revealing that tralokinumab failed to meet its primary endpoints in the treatment of asthma.

7. Novartis to bolster oncology portfolio with $3.9 billion acquisition

Novartis has announced its intention to acquire France’s Advanced Accelerator Applications (AAA) for $3.9 billion in a move to reinforce its oncology portfolio.

6. Switching Crohn's patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says

Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to the biosimilar from its reference pproduct Remicade (infliximab) is comparably safe and effective to treatment with Remicade alone over a 24-week period.

5. CAR-T is bringing true precision to the fight against cancer

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment is changed forever.

4. Pfizer to begin auction of consumer health division next month

Pfizer is planning to launch an auction process to secure its sale and the $15 billion-plus it is looking for the unit, it has emerged.

3. MSD withdraws European application of Keytruda combo in lung cancer

MSD has been forced to withdraw its EU marketing application for Keytruda in combination with pemetrexed and carboplatin in non-small cell lung cancer, despite the combination already gaining approval in the US back in May this year.

2. Novartis reveals the data behind its showdown with Gilead

Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is approved in, today it revealed the data behind this decision to encroach on its rival’s turf.

1. Samsung Biologics reinforces biologic manufacturing and development partnership with MSD

Samsung Biologics has announced it has expanded its strategic alliance with MSD to streamline process development and clinical material production for small biotech start-ups focusing on novel drugs.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches